Key Highlights

● Recursion Pharmaceuticals climbed solidly on Friday as biotech stocks rallied, with no announcement from the company.

● Recursion uses artificial intelligence, automation and large biological datasets to discover and develop drug candidates.

● A media report said the NIH plans a public-private cancer Vaccine Partnership starting in December, modeled on Covid-19 vaccine development.

● AI-linked software rebounded after Thursday's OpenAI Revenue report, giving Recursion a second tailwind alongside biotech.

Recursion Pharmaceuticals (NASDAQ:RXRX) climbed solidly on Friday, joining a long list of biotechnology stocks that rallied after a media report about a federal push into cancer vaccines. Market reports named Recursion among the companies that jumped on the news, alongside vaccine makers and other research-driven biotechs.

Recursion did not issue an announcement of its own. The move reflected the sector's response to the report rather than a development at the company.

Recursion uses artificial intelligence, automation and large biological datasets to discover and develop drug candidates, an approach that blends technology with traditional pharmaceutical research. That dual identity meant the stock had two tailwinds on Friday: the biotech rally and a rebound in technology and AI-linked software shares.

What the report said

According to a media report, the National Institutes of Health plans a public-private partnership to fast-track cancer vaccine research, starting in December. The initiative is expected to focus initially on pancreatic, liver and colorectal cancers, along with some childhood tumors, and is modeled on the rapid development of Covid-19 vaccines.

The response was immediate. Moderna (NASDAQ:MRNA) rose $28.00 to $225.00, reaching its highest level since 2021 on the same day it officially rejoined the Nasdaq-100. Novavax (NASDAQ:NVAX) soared, and BioNTech (NASDAQ:BNTX) and Arcturus Therapeutics (NASDAQ:ARCT) jumped. Ginkgo Bioworks (NYSE:DNA), Twist Bioscience (NASDAQ:TWST) and Tempus (NASDAQ:TEM) AI were among other technology-heavy life-science names mentioned in market coverage as part of the rally. Larger drugmakers such as Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Gilead Sciences (NASDAQ:GILD) also gained.

AI's rebound helped too

Friday also saw a rebound in AI-related software stocks after a bruising Thursday. A media report had said that OpenAI's annualized revenue was about $50 billion at the end of September, well below a figure that had circulated earlier, sparking a selloff across the AI complex. On Friday, software and Cybersecurity stocks rallied strongly, although chipmakers lagged.

For a company like Recursion, which sits at the intersection of AI and drug discovery, a recovery in sentiment toward AI applications can add to the appeal when biotech is also in favor.

Market snapshot

The Nasdaq Composite rose 172.83 points to 27,366.17, the S&P 500 added 46.18 points to 7,811.54 and the Dow Jones Industrial Average gained 423.31 points to 51,654.95. Health care was one of the top-performing sectors in the S&P 500, behind only real estate, while communication services lagged as wireless carriers slumped on SpaceX (NASDAQ:SPCX)'s spectrum deal. The Cboe Volatility index eased to 14.84.

Theme-driven rallies in biotech can reverse quickly, however. Such shares often swing sharply in both directions, and early-stage drug developers remain sensitive to borrowing costs. The 10-year Treasury Yield held near a 24-year high, and the Federal Reserve raised rates in September for the first time since 2023.

NIH Initiative Detail and Recursion's Pipeline and Partnership Updates Are the Next Drivers

Markets also face September consumer price data on Wednesday, October 14, a Columbus Day session on Monday when stocks trade but bonds do not, and the Federal Reserve's October 27–28 meeting. Further details of the NIH initiative ahead of its expected December start could keep biotech stocks volatile. For Recursion, updates on its clinical pipeline and partnerships will be the most direct drivers. Johnson & Johnson (NYSE:JNJ)'s results on Tuesday, October 13, will offer an early read on health care this Earnings season.